Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,021 INR | +2.26% | +2.52% | +25.86% |
Apr. 09 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
Mar. 27 | NATCO Pharma Limited Announces Board Appointments | CI |
Sales 2024 * | 39.19B 471M | Sales 2025 * | 45.13B 542M | Capitalization | 183B 2.2B |
---|---|---|---|---|---|
Net income 2024 * | 13.21B 159M | Net income 2025 * | 15.27B 183M | EV / Sales 2024 * | 4.27 x |
Net cash position 2024 * | 15.67B 188M | Net cash position 2025 * | 31.57B 379M | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
13.9
x | P/E ratio 2025 * |
12.1
x | Employees | 3,946 |
Yield 2024 * |
0.98% | Yield 2025 * |
1.11% | Free-Float | 46.76% |
Latest transcript on NATCO Pharma Limited
1 day | +2.26% | ||
1 week | +2.52% | ||
Current month | +7.26% | ||
1 month | +7.26% | ||
3 months | +17.40% | ||
6 months | +27.94% | ||
Current year | +25.86% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 00-07-02 | |
Founder | 78 | 81-09-18 | |
Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 81-09-18 | |
Chief Executive Officer | 46 | 00-07-02 | |
Director/Board Member | 70 | 14-04-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +0.16% | - | |
0.00% | 34 M€ | +2.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1,021 | +2.26% | 1,288,313 |
24-04-24 | 998.6 | -2.37% | 367,850 |
24-04-23 | 1,023 | +1.70% | 639,513 |
24-04-22 | 1,006 | +0.63% | 624,944 |
24-04-19 | 999.4 | +0.34% | 534,620 |
Delayed Quote NSE India S.E., April 25, 2024 at 09:03 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.86% | 2.15B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+7.95% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B |
- Stock Market
- Equities
- NATCOPHARM Stock